Rivaroxaban Outmatched by VKAs for AF in Rheumatic Heart Disease Rivaroxaban Outmatched by VKAs for AF in Rheumatic Heart Disease

A striking and unexpected reduction in death with the use of predominantly warfarin was just one of the many surprises delivered by the INVICTUS trial at ESC 2022.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news